B
BrightHeart
Biotech & Life Sciences · Paris, France · Founded 2022
FDA-cleared AI for expert-level fetal heart screening in prenatal ultrasound MoreLess
BrightHeart is a Paris medtech company founded in October 2022 from the clinical insight of fetal cardiologists Dr Marilyne Levy and Dr Bertrand Stos, with CEO Cécile Dupont (Sofinnova Partners). Its B-Right AI Platform embeds expert-level fetal-heart screening into routine obstetric ultrasound—guiding views, checking exam completeness and flagging structural abnormalities suggestive of congenital heart defects (CHD)—without forcing clinicians to change how they scan. The company cites multiple FDA 510(k) clearances, peer-reviewed clinical evidence and detection performance above 96% in validated settings, addressing historically low prenatal CHD detection rates. After a €2 million Sofinnova seed in 2023, in January 2026 BrightHeart raised an €11 million Series A co-led by Odyssée Venture and GO Capital, with Sofinnova Partners, Mussallem CHD Alliance, Lift Value, IDAHO HealthTech Club via Side Angels and clinician angels, to commercialise in the US and expand across Europe. Sources: Tech.eu / Sofinnova / BusinessWire 8 Jan 2026; brightheart.ai.
Talent graph
BrightHeart's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where BrightHeart has talent and traffic
team presence
Market sentiment
What the market is saying about BrightHeart
An AI-synthesized read of the highest-engagement posts about BrightHeart on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BrightHeart on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.